Prof Bernard Prendergast (London, UK) meets with Chair, Prof Mauro Biffi, to discuss the management of valve disease in patients during the COVID-19 pandemic. He will look at how to diagnose VHD and identify what determines the need for clinical assessment.
He will consider the risks for patients, as access to intervention and follow-up is limited, looking at ways to diagnose from a distance. He explains how physicians can identify which patients need to be seen and considers the various interventions to treat VHD, and the use of optimal medical therapy to ‘hold’ patients in the meantime.
Reproduced with permission from the British Heart Rhythm Society.
